Source:http://linkedlifedata.com/resource/pubmed/id/17439923
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2007-4-18
|
pubmed:abstractText |
We utilized a mice model of Parkinsonism: (1) to evaluate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity; and (2) to evaluate whether manganese (Mn) exposure can affect MPTP-induced neurotoxicity. A 2 x 3 experimental design (MPTP x+/- Mn) was as follows: SS, MPTP(-) x Mn(-); SLMn, MPTP(-) x low Mn(+); SHMn, MPTP(-) x high Mn(+); MpS, MPTP(+) x Mn(-); MpLMn, MPTP(+) x low Mn(+); MpHMn, MPTP(+) x high Mn(+). We administered MPTP (30 mg/kg per day) to male C57BL/6 mice intraperitoneally, once a day for 5 days. Subsequently, mice were treated with either 2 or 8 mg/kg of MnCl(2).4H(2)O intraperitoneally, once a day for 3 weeks. Blood and striatal Mn levels were elevated in the Mnexposed groups. The number of tyrosine hydroxylase (TH)-immunoreactive (ir) neurons in the substantia nigra pars compacta were decreased significantly in the MPTP-exposed groups. The densities of TH-ir axon terminals in caudate-putamen (CPU) were significantly decreased in the MPTP-treated groups. However, Mn treatment did not affect MPTP neurotoxicity. The densities of glial fibrillary acidic protein (GFAP)-ir astrocytes in the CPU or globus pallidus were significantly increased in the MPTP-treated groups. Concentrations of dopamine in the striatum were decreased significantly in the MPTP-exposed groups only, but Mn had no effect.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1-Methyl-4-phenyl-1,2,3,6-tetrahydro...,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Glial Fibrillary Acidic Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Manganese,
http://linkedlifedata.com/resource/pubmed/chemical/Neurotoxins,
http://linkedlifedata.com/resource/pubmed/chemical/Tyrosine 3-Monooxygenase
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0960-3271
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
203-11
|
pubmed:dateRevised |
2009-11-3
|
pubmed:meshHeading |
pubmed-meshheading:17439923-1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine,
pubmed-meshheading:17439923-Animals,
pubmed-meshheading:17439923-Corpus Striatum,
pubmed-meshheading:17439923-Disease Models, Animal,
pubmed-meshheading:17439923-Dopamine,
pubmed-meshheading:17439923-Dopamine Agents,
pubmed-meshheading:17439923-Drug Interactions,
pubmed-meshheading:17439923-Glial Fibrillary Acidic Protein,
pubmed-meshheading:17439923-MPTP Poisoning,
pubmed-meshheading:17439923-Male,
pubmed-meshheading:17439923-Manganese,
pubmed-meshheading:17439923-Mice,
pubmed-meshheading:17439923-Mice, Inbred C57BL,
pubmed-meshheading:17439923-Neurotoxins,
pubmed-meshheading:17439923-Tyrosine 3-Monooxygenase
|
pubmed:year |
2007
|
pubmed:articleTitle |
Manganese does not alter the severe neurotoxicity of MPTP.
|
pubmed:affiliation |
Department of Anatomy, Pusan National University Medical School, Busan, South Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|